PLMA_1170x120_10-8-21

Albert Bourla

Pfizer reports COVID-19 vaccine 90% effective in Phase 3 trial

Pfizer reports COVID-19 vaccine 90% effective in Phase 3 trial

NEW YORK — Pfizer announced on Monday that the vaccine the company jointly developed with BioNTech was 90% effective in preventing COVID-19 infections in ongoing Phase 3 trials. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. “The first set of

Pfizer to organize into three businesses for future growth

Pfizer to organize into three businesses for future growth

NEW YORK — Pfizer Inc. announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an off-patent branded and generic Established Medicines business operating with substantial autonomy within Pfizer and a Consumer Healthcare business. These

Pfizer mulls possible sale of consumer health unit

Pfizer mulls possible sale of consumer health unit

NEW YORK — Pfizer Inc. is assessing strategic options for its Pfizer Consumer Healthcare subsidiary, including a potential sale. The pharmaceutical giant said this week that it’s considering “a full or partial separation of the Consumer Healthcare business from Pfizer through a spin-off, sale or other transaction.” However, the company noted that it may decided

Pfizer to buy Medivation for $14 billion

Pfizer to buy Medivation for $14 billion

NEW YORK  — Boosting its oncology portfolio, Pfizer Inc. plans to acquire biopharmaceutical company Medivation for $14 billion in cash. Under the deal announced Monday, Pfizer is paying $81.50 a share in cash for San Francisco-based Medivation, whose products include XTANDI (enzalutamide), an androgen receptor inhibitor that the companies said is the nation’s leading novel